AstraZeneca to acquire Alexion for $39 billion
MLex Summary: AstraZeneca is acquiring Alexion for $39 billion. The companies say the merger will combine AstraZeneca’s capabilities in genomics and precision medicine with Alexion’s expertise in complement biology to enable the...To view the full article, register now.
Already a subscriber? Click here to view full article